
GRTS Stock Forecast & Price Target
GRTS Analyst Ratings
Bulls say
Gritstone Bio Inc is advancing its pipeline of personalized cancer immunotherapies, showcasing promising clinical activity in its GRANITE product candidate, particularly among high-risk patients who experienced a significant reduction in progression risk and improved median progression-free survival rates. The company’s successful optimization of the vaccine cassette has demonstrated enhanced immune responses, which bodes well for future regulatory interactions with the FDA regarding the Phase 3 trial design. Additionally, the reported 100% manufacturing success rate for the GRTS samRNA vaccine and its effectiveness in producing durable immune responses in patients living with HIV underscores the potential of Gritstone’s immunotherapy platform and reinforces a positive outlook for the company’s future endeavors.
Bears say
Gritstone Bio faces a negative outlook primarily due to potential adverse safety and efficacy findings in current trials, which could necessitate downward revisions to financial projections. The possibility of a more complex and prolonged regulatory pathway for the company’s immunotherapy candidates further threatens to impact estimates unfavorably. Additionally, equity dilution from funding raises and associated warrants has prompted a reduction in the estimated value of the stock, highlighting the challenges the company faces in achieving a successful commercial trajectory.
This aggregate rating is based on analysts' research of Gritstone Oncology Inc and is not a guaranteed prediction by Public.com or investment advice.
GRTS Analyst Forecast & Price Prediction
Start investing in GRTS
Order type
Buy in
Order amount
Est. shares
0 shares